GlassScriptPhysician profile
Samantha Tuttle
NPI 1700572245
$1,740.31
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.58 · 2023: $802 · 2024: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $151.71 | 2022-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $136.84 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $129.70 | 2023-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $124.19 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.15 | 2023-2024 | Jardiance |
| Exact Sciences Corporation | $108.47 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.06 | 2023-2024 | Xifaxan |
| Pfizer INC. | $102.56 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $92.09 | 2023-2024 | Xarelto |
| Amgen INC. | $89.02 | 2023-2024 | Repatha |
| Abiomed | $79.45 | 2023-2024 | Impella |
| Novo Nordisk INC | $66.28 | 2023-2024 | Ozempic, Wegovy, Rybelsus |
| Lexicon Pharmaceuticals, INC. | $59.90 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $49.76 | 2023 | Nexletol |
| Scpharmaceuticals INC. | $46.73 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $43.22 | 2023-2024 | (Ak6) Vest Therapy |
| Lucid Diagnostics INC. | $41.24 | 2023 | |
| Phathom Pharmaceuticals, INC. | $40.30 | 2024 | Voquezna |
| Coherus Oncology, INC. | $39.50 | 2024 | |
| Boston Scientific Corporation | $33.98 | 2024 | |
| Biogen, INC. | $26.39 | 2024 | Skyclarys |
| Glaxosmithkline, LLC. | $23.35 | 2024 | Trelegy Ellipta, Arexvy |
| Sanofi Pasteur INC. | $18.31 | 2023 | |
| Impulse Dynamics (USA) INC. | $17.11 | 2024 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Tuttle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.